LY3022855

DRUG3 trials

Sponsors

Eli Lilly and Company, Dana-Farber Cancer Institute

Conditions

MelanomaNeoplasm MetastasisNeoplasmsSolid Tumor

Phase 1

A Study of LY3022855 In Participants With Breast or Prostate Cancer

CompletedNCT02265536

Eli Lilly and CompanyNeoplasm Metastasis, Neoplasms

Start: 2015-05-01End: 2017-11-03Updated: 2024-10-28

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

CompletedNCT02718911

Eli Lilly and CompanySolid Tumor

Start: 2016-06-16End: 2018-12-14Updated: 2023-10-16

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

CompletedNCT03101254

Dana-Farber Cancer InstituteMelanoma

Start: 2017-06-06End: 2020-11-11Updated: 2024-07-17

Related Papers

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.

2021-08-0136 citations

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

2021-04-1444 citations

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

Journal of Clinical Oncology2019-05-2017 citations